Clinical Trials Directory

Trials / Completed

CompletedNCT03192488

Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
13 (actual)
Sponsor
Indiana University · Academic / Other
Sex
All
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

This study seeks to determine whether a simple, single intervention of Cetirizine / Zyrtec® use can improve exercise performance of active individuals when acutely exposed to altitude. For this project, healthy subjects will perform steady state and progressive work rate exercise, endurance performance time trials, and repeated sprint performance time trials in the laboratory at a simulated altitude of 3000m (9900ft) after dosing with 10 mg of Cetirizine or a placebo in a repeated measures design.

Detailed description

This study seeks to determine whether a simple, single intervention of Cetirizine / Zyrtec® use can improve exercise performance of active individuals when acutely exposed to altitude. For this project, healthy subjects will perform steady state and progressive work rate exercise, endurance performance time trials, and repeated sprint performance time trials in the laboratory at a simulated altitude of 3000m (9900ft) after dosing with 10 mg of Cetirizine or a placebo in a repeated measures design. Non-invasive techniques (pulse oximetry, near-infrared spectroscopy \[NIRS\]) will be utilized to measure changes in arterial oxyhemoglobin saturation and skeletal muscle oxygenation at the level of the microvasculature during exercise. It is expected that after Cetirizine, blood and muscle microvascular oxygenation during heavy exercise will improve compared to placebo, ultimately improving exercise performance at altitude. Subjects will be asked to report to the laboratory on a three occasions, separated by a minimum of 48 hours and a maximum of 14 days. For each subject, all testing sessions will be performed at the same time of day. Prior to each testing session, subjects will be asked to abstain from caffeine consumption for 12 hours. Subjects will also be asked to avoid alcohol consumption for 24 hours before testing, be at least 3-hour post prandial and avoid high-intensity exercise during the 24 hours leading to the exercise testing. Finally, subjects will be asked to consume a similar diet the night before, and the morning of, Sessions 2 and 3.

Conditions

Interventions

TypeNameDescription
DRUGCetirizineCetirizine tablet 10 mg
DRUGPlacebo oral capsuleGelatin placebo
OTHERHypoxiaExposure to a 14.3% oxygen environment simulating an altitude of 3,000m/9,000ft

Timeline

Start date
2017-08-31
Primary completion
2018-06-06
Completion
2018-06-06
First posted
2017-06-20
Last updated
2020-06-16
Results posted
2020-06-16

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03192488. Inclusion in this directory is not an endorsement.